ENDEAVOR HEALTH CLINICAL OPERATIONS

EVANSTON, IL

OncologyantibodyPhase II

Compare Sign in to watch

What changed

NIH R01 · $0.8M · Next generation in-vivo diffusion imaging at submillimeter resolution

5w agoGrant renewalJun 10, 2026Source filing (opens the source filing in a new tab)

Momentum

100no change

Accelerating: several high-weight events landed recently.

Runway (estimate)

—unknown

No disclosed raise on file, so there is nothing to model from.

Stage

Phase II

The furthest-along thing in the public record. Not a projection.

Runway is an estimate: the last disclosed raise (SEC Form D) minus a modeled burn rate for the company’s stage and therapeutic area. It is not a disclosure, and companies routinely raise non-dilutive money we can’t see. How this is calculated.

Peer position

1,259 pre-ticker oncology companies at Phase II

Peer ranking — where this company sits among its stage-and-area peers by momentum, and how its runway compares to the peer median — is part of the Analyst tier.

Compare seats

A ranking of the same momentum figure the feed publishes, computed live against public-filing peers. It is a relative position, not a recommendation, and it is identical for every viewer.

Grant to raise

Every record Biodatica has resolved onto this company, newest first, each linked to the filing it came from. Where a source publishes no stable deep link for a record, the identifier is shown so you can look it up yourself.

Trial
PHASE2 registered
Apr 10, 2026
Bladder Cancer, Non-Muscle Invasive Bladder Cancer (NMIBC), Urothelial Carcinoma, Carcinoma in Situ (CIS), High-Grade Papillary Bladder Tumors, BCG-Unresponsive Bladder Cancer, Ta Stage Bladder Cancer, T1 Stage Bladder Cancer, BCG-Refractory Bladder Cancer, High-Risk NMIBC, Micropapillary Variant Urothelial Carcinoma (Favorable Subtype) · RECRUITING · sponsor: Michael A. O'Donnell · Intravesical GEM/DOCE for HR BCG-Unresponsive NMIBC
ClinicalTrials.gov · NCT07322263 (opens the source filing in a new tab)
Grant
K24 · $210k · non-dilutive
Sep 15, 2025
COLUMBIA UNIVERSITY HEALTH SCIENCES · PI O'DONNELL, MAX · NIAID · award ends Aug 31, 2030 · Mentoring Multidisciplinary Research in MDR-TB Adherence and the Emergent Drug Resistance
NIH RePORTER · NIH RePORTER 11190297 (opens the source filing in a new tab)
Grant
R21 · $253k · non-dilutive
Sep 9, 2025
COLUMBIA UNIVERSITY HEALTH SCIENCES · PI O'DONNELL, MAX · NIAID · award ends Aug 31, 2027 · Mobilizing Innovative Strategies to Improve TB Diagnosis and Retention in the TB Care Cascade for Migrant Communities in New York City
NIH RePORTER · NIH RePORTER 11246771 (opens the source filing in a new tab)
Grant
P01 · $338k · non-dilutive
May 15, 2025
WASHINGTON UNIVERSITY · PI O'DONNELL, JAMES · NHLBI · award ends Apr 30, 2030 · Role of glycans in VWF biology and VWD pathogenesis
NIH RePORTER · NIH RePORTER 11016813 (opens the source filing in a new tab)
Grant
P01 · $316k · non-dilutive
May 15, 2025
WASHINGTON UNIVERSITY · PI O'DONNELL, JAMES · NHLBI · award ends Apr 30, 2030 · Role of glycans in VWF biology and VWD pathogenesis
NIH RePORTER · NIH RePORTER 11327279 (opens the source filing in a new tab)
Grant
R35 · $377k · non-dilutive
Apr 15, 2025
UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI O'DONNELL, ALLYSON F. · NIGMS · award ends Mar 31, 2030 · Mechanisms of alpha-arrestin-mediated protein trafficking
NIH RePORTER · NIH RePORTER 11011531 (opens the source filing in a new tab)
Grant
R35 · $377k · non-dilutive
Apr 15, 2025
UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI O'DONNELL, ALLYSON F. · NIGMS · award ends Mar 31, 2030 · Mechanisms of alpha-arrestin-mediated protein trafficking
NIH RePORTER · NIH RePORTER 11314491 (opens the source filing in a new tab)
Grant
R21 · $73k · non-dilutive
Aug 20, 2024
COLUMBIA UNIVERSITY HEALTH SCIENCES · PI HIRSCH-MOVERMAN, YAEL R · NIAID · award ends Jul 31, 2027 · Rifapentine in High Doses in Pregnancy with TB (Radiant-Moms) study
NIH RePORTER · NIH RePORTER 11173908 (opens the source filing in a new tab)
Grant
R21 · $36k · non-dilutive
Aug 20, 2024
COLUMBIA UNIVERSITY HEALTH SCIENCES · PI HIRSCH-MOVERMAN, YAEL R · NIAID · award ends Jul 31, 2027 · Rifapentine in High Doses in Pregnancy with TB (Radiant-Moms) study
NIH RePORTER · NIH RePORTER 11400224 (opens the source filing in a new tab)
Grant
R21 · $39k · non-dilutive
Aug 20, 2024
COLUMBIA UNIVERSITY HEALTH SCIENCES · PI HIRSCH-MOVERMAN, YAEL R · NIAID · award ends Jul 31, 2027 · Rifapentine in High Doses in Pregnancy with TB (Radiant-Moms) study
NIH RePORTER · NIH RePORTER 11400225 (opens the source filing in a new tab)
Trial
NA registered
Jul 30, 2024
Adult Patients Who Are Receiving Oncologic Care · RECRUITING · sponsor: University of Chicago · Informing Pain Treatment Using Pharmacogenomic Analysis
ClinicalTrials.gov · NCT06511401 (opens the source filing in a new tab)
Grant
R21 · $334k · non-dilutive
Feb 15, 2024
ENDEAVOR HEALTH CLINICAL OPERATIONS · PI DAVID, SEAN P. · NHGRI · award ends Jan 31, 2027 · Integrative Analyses of Clinical Pharmacogenetic Data to Prevent Hospital Readmission in Real-World Health Systems
NIH RePORTER · NIH RePORTER 11030241 (opens the source filing in a new tab)
Trial
PHASE2 registered
Sep 5, 2023
Brain Metastases · RECRUITING · sponsor: University of Chicago · Frameless Stereotactic Radiosurgery for Intact Brain Metastases
ClinicalTrials.gov · NCT02747303 (opens the source filing in a new tab)
Grant
R35 · $424k · non-dilutive
Sep 1, 2023
ROCKEFELLER UNIVERSITY · PI O'DONNELL, MICHAEL E · NIGMS · award ends May 31, 2028 · Biochemistry of Eukaryotic Replication Fork and DNA Repair
NIH RePORTER · NIH RePORTER 11330174 (opens the source filing in a new tab)
Grant
RF1 · $1.7M · non-dilutive
Jun 20, 2023
BRIGHAM AND WOMEN'S HOSPITAL · PI O'DONNELL, LAUREN JEAN · NIMH · award ends Mar 31, 2028 · Mapping of the intrinsic and extrinsic cerebellar connectome at ultra high resolution with expert neuroanatomical curation
NIH RePORTER · NIH RePORTER 11321693 (opens the source filing in a new tab)
Grant
R01 · $867k · non-dilutive
Jun 1, 2023
UNIVERSITY OF CHICAGO · PI O'DONNELL, PETER HUGH · NHGRI · award ends Mar 31, 2028 · Pharmacogenomics to Catalyze Decision Support in Oncology Care
NIH RePORTER · NIH RePORTER 11058536 (opens the source filing in a new tab)
Grant
R01 · $868k · non-dilutive
Jun 1, 2023
UNIVERSITY OF CHICAGO · PI O'DONNELL, PETER HUGH · NHGRI · award ends Mar 31, 2028 · Pharmacogenomics to Catalyze Decision Support in Oncology Care
NIH RePORTER · NIH RePORTER 11328802 (opens the source filing in a new tab)
Grant
R01 · $732k · non-dilutive
Apr 3, 2023
COLUMBIA UNIVERSITY HEALTH SCIENCES · PI O'DONNELL, MAX · NIAID · award ends Mar 31, 2028 · Rapid phenotypic detection of complex and emergent TB drug-resistance using a next-generation nanoluciferase reporter phage
NIH RePORTER · NIH RePORTER 11078830 (opens the source filing in a new tab)
Grant
R01 · $718k · non-dilutive
Apr 3, 2023
COLUMBIA UNIVERSITY HEALTH SCIENCES · PI O'DONNELL, MAX · NIAID · award ends Mar 31, 2028 · Rapid phenotypic detection of complex and emergent TB drug-resistance using a next-generation nanoluciferase reporter phage
NIH RePORTER · NIH RePORTER 11419782 (opens the source filing in a new tab)
Trial
NA registered
Mar 7, 2023
Multi Drug Resistant Tuberculosis, HIV Infections · RECRUITING · sponsor: Columbia University · An Adaptive Randomized Controlled Trial
ClinicalTrials.gov · NCT05633056 (opens the source filing in a new tab)
Grant
R01 · $256k · non-dilutive
Mar 10, 2022
COLUMBIA UNIVERSITY HEALTH SCIENCES · PI O'DONNELL, MAX · NIAID · award ends Feb 28, 2027 · Adaptive evaluation of mHealth and conventional adherence support interventions to optimize outcomes with new treatment regimens for drug-resistant tuberculosis and HIV in South Africa
NIH RePORTER · NIH RePORTER 11047560 (opens the source filing in a new tab)
Grant
R01 · $280k · non-dilutive
Mar 10, 2022
COLUMBIA UNIVERSITY HEALTH SCIENCES · PI O'DONNELL, MAX · NIAID · award ends Feb 28, 2027 · Adaptive evaluation of mHealth and conventional adherence support interventions to optimize outcomes with new treatment regimens for drug-resistant tuberculosis and HIV in South Africa
NIH RePORTER · NIH RePORTER 11397169 (opens the source filing in a new tab)
Grant
R01 · $14k · non-dilutive
Mar 10, 2022
COLUMBIA UNIVERSITY HEALTH SCIENCES · PI O'DONNELL, MAX · NIAID · award ends Feb 28, 2027 · Adaptive evaluation of mHealth and conventional adherence support interventions to optimize outcomes with new treatment regimens for drug-resistant tuberculosis and HIV in South Africa
NIH RePORTER · NIH RePORTER 11397170 (opens the source filing in a new tab)
Grant
R01 · $316k · non-dilutive
Mar 10, 2022
COLUMBIA UNIVERSITY HEALTH SCIENCES · PI O'DONNELL, MAX · NIAID · award ends Feb 28, 2027 · Adaptive evaluation of mHealth and conventional adherence support interventions to optimize outcomes with new treatment regimens for drug-resistant tuberculosis and HIV in South Africa
NIH RePORTER · NIH RePORTER 11414832 (opens the source filing in a new tab)
Grant
R01 · $223k · non-dilutive
Mar 10, 2022
COLUMBIA UNIVERSITY HEALTH SCIENCES · PI O'DONNELL, MAX · NIAID · award ends Feb 28, 2027 · Adaptive evaluation of mHealth and conventional adherence support interventions to optimize outcomes with new treatment regimens for drug-resistant tuberculosis and HIV in South Africa
NIH RePORTER · NIH RePORTER 11472086 (opens the source filing in a new tab)
Grant
R01 · $14k · non-dilutive
Mar 10, 2022
COLUMBIA UNIVERSITY HEALTH SCIENCES · PI O'DONNELL, MAX · NIAID · award ends Feb 28, 2027 · Adaptive evaluation of mHealth and conventional adherence support interventions to optimize outcomes with new treatment regimens for drug-resistant tuberculosis and HIV in South Africa
NIH RePORTER · NIH RePORTER 11472087 (opens the source filing in a new tab)
Trial
NA registered
Feb 7, 2022
Gastrointestinal Cancer, Head and Neck Cancer, Dihydropyrimidine Dehydrogenase Deficiency, UGT1A1 Gene Mutation, Breast Cancer · SUSPENDED · sponsor: University of Chicago · The PhOCus Trial: Implementation of Pharmacogenomic Testing in Oncology Care
ClinicalTrials.gov · NCT04541381 (opens the source filing in a new tab)
Trial
PHASE2 registered
Feb 19, 2021
Mesothelioma, Homologous Recombination Deficiency · RECRUITING · sponsor: University of Chicago · Olaparib in Patients With HRD Malignant Mesothelioma
ClinicalTrials.gov · NCT04515836 (opens the source filing in a new tab)
Grant
IK2 · non-dilutive
Feb 1, 2021
PHILADELPHIA VA MEDICAL CENTER · PI O'DONNELL, JOHN CHARLES · VA · award ends Jan 31, 2027 · Translational Modeling of Brain Injury Rehabilitation to Maximize Recovery.
NIH RePORTER · NIH RePORTER 11465348 (opens the source filing in a new tab)
Grant
R01 · $750k · non-dilutive
Nov 1, 2020
STANFORD UNIVERSITY · PI SETSOMPOP, KAWIN · NIMH · award ends Jun 30, 2029 · Next generation in-vivo diffusion imaging at submillimeter resolution
NIH RePORTER · NIH RePORTER 11399166 (opens the source filing in a new tab)
Grant
UG1 · $701k · non-dilutive
Mar 6, 2019
UNIVERSITY OF CHICAGO · PI KINDLER, HEDY L · NCI · award ends Feb 29, 2032 · UG1 - NCTN (Network Lead)
NIH RePORTER · NIH RePORTER 11291466 (opens the source filing in a new tab)
Trial
Study registered
Nov 9, 2017
Information Seeking Behavior · RECRUITING · sponsor: University of Chicago · Implementation of Point-of-Care Pharmacogenomic Decision Support Accounting for Minority Disparities
ClinicalTrials.gov · NCT03225820 (opens the source filing in a new tab)
Grant
R01 · $325k · non-dilutive
Feb 1, 2016
OREGON HEALTH & SCIENCE UNIVERSITY · PI DAVID, STEPHEN V · NIDCD · award ends Oct 31, 2026 · Sound encoding by neural populations in auditory cortex during behavior
NIH RePORTER · NIH RePORTER 11146648 (opens the source filing in a new tab)
Trial
PHASE2 registered
Mar 31, 2015
Biphasic Mesothelioma, Epithelioid Mesothelioma, Peritoneal Malignant Mesothelioma, Pleural Biphasic Mesothelioma, Pleural Epithelioid Mesothelioma, Pleural Malignant Mesothelioma, Pleural Sarcomatoid Mesothelioma, Recurrent Peritoneal Malignant Mesothelioma, Recurrent Pleural Malignant Mesothelioma, Sarcomatoid Mesothelioma · COMPLETED · sponsor: University of Chicago · Pembrolizumab in Treating Patients With Malignant Mesothelioma
ClinicalTrials.gov · NCT02399371 (opens the source filing in a new tab)
Grant
T32 · $326k · non-dilutive
Sep 1, 2014
COLUMBIA UNIVERSITY HEALTH SCIENCES · PI HIRSCH-MOVERMAN, YAEL R · NIAID · award ends Aug 31, 2029 · Global HIV Implementation Science Research Training Grant
NIH RePORTER · NIH RePORTER 11135465 (opens the source filing in a new tab)
Trial
Study registered
Jan 14, 2011
Patients Undergoing Routine Health Care, Heart Diseases, Inflammatory Bowel Diseases, Autoimmune Disease, Inflammatory Disease, Blood Coagulation Disorders, Hepatitis C, Non-Metastatic Neoplasm · RECRUITING · sponsor: University of Chicago · The 1200 Patients Project: Studying the Implementation of Clinical Pharmacogenomic Testing
ClinicalTrials.gov · NCT01280825 (opens the source filing in a new tab)
Grant
P30 · $243k · non-dilutive
Sep 1, 2010
UT SOUTHWESTERN MEDICAL CENTER · PI O'DONNELL, KATHRYN ANN · NCI · award ends Jul 31, 2026 · Development and Cancer Program
NIH RePORTER · NIH RePORTER 11138694 (opens the source filing in a new tab)
Trial
PHASE2 registered
Sep 14, 2005
Gastrointestinal Stromal Tumor · ACTIVE_NOT_RECRUITING · sponsor: National Cancer Institute (NCI) · Sorafenib in Treating Patients With Malignant Gastrointestinal Stromal Tumor That Progressed During or After Previous Treatment With Imatinib Mesylate and Sunitinib Malate
ClinicalTrials.gov · NCT00265798 (opens the source filing in a new tab)
Grant
R01 · $282k · non-dilutive
Jul 15, 1995
UNIVERSITY OF CALIFORNIA AT DAVIS · PI DAVID, SHEILA SUE · NCI · award ends Jun 30, 2027 · DNA Damage Repair by MUTYH and MUTYH Variants Associated with Colorectal Cancer
NIH RePORTER · NIH RePORTER 11109409 (opens the source filing in a new tab)
Grant
T32 · $574k · non-dilutive
Jul 1, 1978
UNIVERSITY OF CHICAGO · PI O'DONNELL, PETER HUGH · NIGMS · award ends Jun 30, 2030 · Clinical Therapeutics
NIH RePORTER · NIH RePORTER 11014780 (opens the source filing in a new tab)

How this crosswalk was built

Confidence 100%Edges merged automatically, not yet reviewed by a human

Shared principal investigator or founder links the trial record at 0.75grant to an academic institution linked by a shared principal investigator
Shared principal investigator or founder links the grant record at 0.75grant to an academic institution linked by a shared principal investigator
Shared principal investigator or founder links the grant record at 0.75grant to an academic institution linked by a shared principal investigator
Shared principal investigator or founder links the grant record at 0.75principal investigator O'DONNELL, JAMES is named on this company's filings
Shared principal investigator or founder links the grant record at 0.75principal investigator O'DONNELL, ALLYSON F. is named on this company's filings
Shared principal investigator or founder links the grant record at 0.75grant to an academic institution linked by a shared principal investigator
Shared principal investigator or founder links the grant record at 0.75grant to an academic institution linked by a shared principal investigator
Shared principal investigator or founder links the grant record at 0.75grant to an academic institution linked by a shared principal investigator
Shared principal investigator or founder links the grant record at 0.75grant to an academic institution linked by a shared principal investigator
Shared principal investigator or founder links the grant record at 0.75grant to an academic institution linked by a shared principal investigator
Shared principal investigator or founder links the grant record at 0.75grant to an academic institution linked by a shared principal investigator
Shared principal investigator or founder links the grant record at 0.75grant to an academic institution linked by a shared principal investigator
Shared principal investigator or founder links the grant record at 0.75grant to an academic institution linked by a shared principal investigator
Shared principal investigator or founder links the grant record at 0.75grant to an academic institution linked by a shared principal investigator
Shared principal investigator or founder links the grant record at 0.75grant to an academic institution linked by a shared principal investigator
Shared principal investigator or founder links the grant record at 0.75grant to an academic institution linked by a shared principal investigator
Shared principal investigator or founder links the grant record at 0.75grant to an academic institution linked by a shared principal investigator
Shared principal investigator or founder links the grant record at 0.75grant to an academic institution linked by a shared principal investigator
Shared principal investigator or founder links the grant record at 0.75grant to an academic institution linked by a shared principal investigator
Shared principal investigator or founder links the grant record at 0.75grant to an academic institution linked by a shared principal investigator
Shared principal investigator or founder links the grant record at 0.75grant to an academic institution linked by a shared principal investigator
Shared principal investigator or founder links the grant record at 0.75grant to an academic institution linked by a shared principal investigator
Shared principal investigator or founder links the grant record at 0.75grant to an academic institution linked by a shared principal investigator
Shared principal investigator or founder links the grant record at 0.75grant to an academic institution linked by a shared principal investigator
Shared principal investigator or founder links the grant record at 0.75grant to an academic institution linked by a shared principal investigator
Shared principal investigator or founder links the grant record at 0.75grant to an academic institution linked by a shared principal investigator
Shared principal investigator or founder links the grant record at 0.75grant to an academic institution linked by a shared principal investigator
Shared principal investigator or founder links the grant record at 0.75grant to an academic institution linked by a shared principal investigator
Shared principal investigator or founder links the grant record at 0.75grant to an academic institution linked by a shared principal investigator
Shared principal investigator or founder links the grant record at 0.75grant to an academic institution linked by a shared principal investigator
Shared principal investigator or founder links the trial record at 0.75grant to an academic institution linked by a shared principal investigator
Shared principal investigator or founder links the trial record at 0.75grant to an academic institution linked by a shared principal investigator
Shared principal investigator or founder links the trial record at 0.75grant to an academic institution linked by a shared principal investigator
Shared principal investigator or founder links the trial record at 0.75grant to an academic institution linked by a shared principal investigator
Shared principal investigator or founder links the trial record at 0.75grant to an academic institution linked by a shared principal investigator
Shared principal investigator or founder links the trial record at 0.75grant to an academic institution linked by a shared principal investigator
Shared principal investigator or founder links the trial record at 0.75grant to an academic institution linked by a shared principal investigator
Shared principal investigator or founder links the trial record at 0.75grant to an academic institution linked by a shared principal investigator
Shared principal investigator or founder links the trial record at 0.75grant to an academic institution linked by a shared principal investigator
new_entity links the grant record at 0.30no candidate cleared the review threshold

Links score at or above 0.86 to merge automatically. Anything below that and above the review line goes to a human queue. Resolution is a judgment, and it can be wrong. How resolution works.

Investigators

The principal investigators named on the grants below. Each links to their federal grant record and every other company traced to their work.

Event stream

Every scored event, newest first. This is what momentum is computed from.

NIH R01 · $0.8M · Next generation in-vivo diffusion imaging at submillimeter resolution
5w agoGrant renewalSource (opens the source filing in a new tab)
Study registered, no phase assigned: An Adaptive Randomized Controlled Trial
7w agoTrial registeredSource (opens the source filing in a new tab)
Trial now recruiting: An Adaptive Randomized Controlled Trial
7w agoTrial recruitingSource (opens the source filing in a new tab)
NIH P01 · $0.3M · Role of glycans in VWF biology and VWD pathogenesis
7w agoGrant renewalSource (opens the source filing in a new tab)
NIH RF1 · $1.7M · Mapping of the intrinsic and extrinsic cerebellar connectome at ultra high resolution with expert neuroanatomical curation
2mo agoGrant renewalSource (opens the source filing in a new tab)
NIH UG1 · $0.7M · UG1 - NCTN (Network Lead)
2mo agoGrant renewalSource (opens the source filing in a new tab)
Phase II trial registered: Pembrolizumab in Treating Patients With Malignant Mesothelioma
2mo agoTrial registeredSource (opens the source filing in a new tab)
Trial completed: Pembrolizumab in Treating Patients With Malignant Mesothelioma
2mo agoTrial completedSource (opens the source filing in a new tab)
Study registered, no phase assigned: The PhOCus Trial: Implementation of Pharmacogenomic Testing in Oncology Care
2mo agoTrial registeredSource (opens the source filing in a new tab)
Study registered, no phase assigned: Informing Pain Treatment Using Pharmacogenomic Analysis
2mo agoTrial registeredSource (opens the source filing in a new tab)
Trial now recruiting: Informing Pain Treatment Using Pharmacogenomic Analysis
2mo agoTrial recruitingSource (opens the source filing in a new tab)
Phase II trial registered: Sorafenib in Treating Patients With Malignant Gastrointestinal Stromal Tumor That Progressed During or After Previous Treatment With Imatinib Mesylate and Sunitinib Malate
2mo agoTrial registeredSource (opens the source filing in a new tab)
NIH R35 · $0.4M · Biochemistry of Eukaryotic Replication Fork and DNA Repair
2mo agoGrant renewalSource (opens the source filing in a new tab)
Study registered, no phase assigned: Implementation of Point-of-Care Pharmacogenomic Decision Support Accounting for Minority Disparities
2mo agoTrial registeredSource (opens the source filing in a new tab)
Trial now recruiting: Implementation of Point-of-Care Pharmacogenomic Decision Support Accounting for Minority Disparities
2mo agoTrial recruitingSource (opens the source filing in a new tab)
NIH R01 · $0.9M · Pharmacogenomics to Catalyze Decision Support in Oncology Care
3mo agoGrant renewalSource (opens the source filing in a new tab)
Phase II trial registered: Intravesical GEM/DOCE for HR BCG-Unresponsive NMIBC
3mo agoTrial registeredSource (opens the source filing in a new tab)
Trial now recruiting: Intravesical GEM/DOCE for HR BCG-Unresponsive NMIBC
3mo agoTrial recruitingSource (opens the source filing in a new tab)
NIH IK2 · Translational Modeling of Brain Injury Rehabilitation to Maximize Recovery.
3mo agoGrant renewalSource (opens the source filing in a new tab)
NIH R01 · $0.7M · Rapid phenotypic detection of complex and emergent TB drug-resistance using a next-generation nanoluciferase reporter phage
3mo agoGrant renewalSource (opens the source filing in a new tab)
NIH R35 · $0.4M · Mechanisms of alpha-arrestin-mediated protein trafficking
3mo agoGrant renewalSource (opens the source filing in a new tab)
Study registered, no phase assigned: The 1200 Patients Project: Studying the Implementation of Clinical Pharmacogenomic Testing
4mo agoTrial registeredSource (opens the source filing in a new tab)
Trial now recruiting: The 1200 Patients Project: Studying the Implementation of Clinical Pharmacogenomic Testing
4mo agoTrial recruitingSource (opens the source filing in a new tab)
NIH R01 · $0.0M · Adaptive evaluation of mHealth and conventional adherence support interventions to optimize outcomes with new treatment regimens for drug-resistant tuberculosis and HIV in South Africa
5mo agoGrant renewalSource (opens the source filing in a new tab)
NIH R01 · $0.2M · Adaptive evaluation of mHealth and conventional adherence support interventions to optimize outcomes with new treatment regimens for drug-resistant tuberculosis and HIV in South Africa
5mo agoGrant renewalSource (opens the source filing in a new tab)
NIH R01 · $0.3M · Adaptive evaluation of mHealth and conventional adherence support interventions to optimize outcomes with new treatment regimens for drug-resistant tuberculosis and HIV in South Africa
5mo agoGrant renewalSource (opens the source filing in a new tab)
Phase II trial registered: Frameless Stereotactic Radiosurgery for Intact Brain Metastases
6mo agoTrial registeredSource (opens the source filing in a new tab)
Trial now recruiting: Frameless Stereotactic Radiosurgery for Intact Brain Metastases
6mo agoTrial recruitingSource (opens the source filing in a new tab)
NIH R21 · $0.0M · Rifapentine in High Doses in Pregnancy with TB (Radiant-Moms) study
10mo agoGrant renewalSource (opens the source filing in a new tab)
NIH R21 · $0.0M · Rifapentine in High Doses in Pregnancy with TB (Radiant-Moms) study
10mo agoGrant renewalSource (opens the source filing in a new tab)
NIH R01 · $0.7M · Rapid phenotypic detection of complex and emergent TB drug-resistance using a next-generation nanoluciferase reporter phage
10mo agoGrant renewalSource (opens the source filing in a new tab)
NIH P30 · $0.2M · Development and Cancer Program
10mo agoGrant renewalSource (opens the source filing in a new tab)
NIH R01 · $0.0M · Adaptive evaluation of mHealth and conventional adherence support interventions to optimize outcomes with new treatment regimens for drug-resistant tuberculosis and HIV in South Africa
10mo agoGrant renewalSource (opens the source filing in a new tab)
NIH K24 · $0.2M · Mentoring Multidisciplinary Research in MDR-TB Adherence and the Emergent Drug Resistance
10mo agoNew grantSource (opens the source filing in a new tab)
NIH R01 · $0.3M · Adaptive evaluation of mHealth and conventional adherence support interventions to optimize outcomes with new treatment regimens for drug-resistant tuberculosis and HIV in South Africa
10mo agoGrant renewalSource (opens the source filing in a new tab)
NIH T32 · $0.3M · Global HIV Implementation Science Research Training Grant
10mo agoGrant renewalSource (opens the source filing in a new tab)
NIH R21 · $0.1M · Rifapentine in High Doses in Pregnancy with TB (Radiant-Moms) study
10mo agoGrant renewalSource (opens the source filing in a new tab)
NIH R01 · $0.3M · Adaptive evaluation of mHealth and conventional adherence support interventions to optimize outcomes with new treatment regimens for drug-resistant tuberculosis and HIV in South Africa
10mo agoGrant renewalSource (opens the source filing in a new tab)
NIH R21 · $0.3M · Mobilizing Innovative Strategies to Improve TB Diagnosis and Retention in the TB Care Cascade for Migrant Communities in New York City
10mo agoNew grantSource (opens the source filing in a new tab)
NIH T32 · $0.6M · Clinical Therapeutics
Jun 2025Grant renewalSource (opens the source filing in a new tab)
NIH R01 · $0.3M · DNA Damage Repair by MUTYH and MUTYH Variants Associated with Colorectal Cancer
Jun 2025Grant renewalSource (opens the source filing in a new tab)
NIH R01 · $0.3M · Sound encoding by neural populations in auditory cortex during behavior
May 2025Grant renewalSource (opens the source filing in a new tab)
NIH R01 · $0.9M · Pharmacogenomics to Catalyze Decision Support in Oncology Care
May 2025Grant renewalSource (opens the source filing in a new tab)
Phase II trial registered: Olaparib in Patients With HRD Malignant Mesothelioma
May 2025Trial registeredSource (opens the source filing in a new tab)
Trial now recruiting: Olaparib in Patients With HRD Malignant Mesothelioma
May 2025Trial recruitingSource (opens the source filing in a new tab)
NIH P01 · $0.3M · Role of glycans in VWF biology and VWD pathogenesis
May 2025New grantSource (opens the source filing in a new tab)
NIH R35 · $0.4M · Mechanisms of alpha-arrestin-mediated protein trafficking
Apr 2025New grantSource (opens the source filing in a new tab)
NIH R21 · $0.3M · Integrative Analyses of Clinical Pharmacogenetic Data to Prevent Hospital Readmission in Real-World Health Systems
Feb 2025Grant renewalSource (opens the source filing in a new tab)

Last disclosed raise

No Form D is on file, so there is no raise to model a runway from. That is why the runway reads “—” rather than a number. It does not mean the company has no money: grants, revenue and notes below the Form D threshold are all invisible here.

Something wrong on this page? The crosswalk is a judgment and we would rather hear it. Report a bad link.

Biodatica publishes impersonal research shown identically to every subscriber. This dossier is informational only, it is not investment advice, and the momentum and runway figures are estimates derived from public filings. The underlying records are U.S. government works. Disclosures · Data sources

Peer position

Grant to raise

PHASE2 registered

K24 · $210k · non-dilutive

R21 · $253k · non-dilutive

P01 · $338k · non-dilutive

P01 · $316k · non-dilutive

R35 · $377k · non-dilutive

R35 · $377k · non-dilutive

R21 · $73k · non-dilutive

R21 · $36k · non-dilutive

R21 · $39k · non-dilutive

NA registered

R21 · $334k · non-dilutive

PHASE2 registered

R35 · $424k · non-dilutive

RF1 · $1.7M · non-dilutive

R01 · $867k · non-dilutive

R01 · $868k · non-dilutive

R01 · $732k · non-dilutive

R01 · $718k · non-dilutive

NA registered

R01 · $256k · non-dilutive

R01 · $280k · non-dilutive

R01 · $14k · non-dilutive

R01 · $316k · non-dilutive

R01 · $223k · non-dilutive

R01 · $14k · non-dilutive

NA registered

PHASE2 registered

IK2 · non-dilutive

R01 · $750k · non-dilutive

UG1 · $701k · non-dilutive

Study registered

R01 · $325k · non-dilutive

PHASE2 registered

T32 · $326k · non-dilutive

Study registered

P30 · $243k · non-dilutive

PHASE2 registered

R01 · $282k · non-dilutive

T32 · $574k · non-dilutive